LOGIN  |  REGISTER
Recursion
Viking Therapeutics

Vor Bio to Participate in Upcoming Investor Conferences

November 03, 2023 | Last Trade: US$1.56 0.08 -4.60

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

Stifel 2023 Healthcare Conference
Fireside Chat: Tuesday, November 14, 2023 at 3:35 pm ET
Location: Lotte New York Palace Hotel, New York, NY

A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.

6th Annual Evercore ISI HealthCONx Conference
Fireside Chat: Wednesday, November 29, 2023 at 3:00 pm ET
Location: Kimpton EPIC Hotel, Miami, FL

Piper Sandler 35th Annual Healthcare Conference
Fireside Chat: Thursday, November 30, 2023 at 2:00 pm ET
Location: Lotte New York Palace Hotel, New York, NY

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page